GeneMedicine.net

Gene Medicine Xagena

Cyclin A2 induces cardiac regeneration after myocardial infarction


After a myocardial infarction, there is often permanent damage to a portion of the heart. This happens, in part, because cardiac muscle cells are terminally differentiated and cannot proliferate after blood flow is blocked off to the heart. This partial healing can be attributed to heart disease being one of the leading causes of death.
What if the cells could be stimulated to divide and the heart could be induced to repair itself ? This was the question posed by Scott Shapiro, at George Washington University, and his co-authors, who found that cardiac regeneration may be a possibility with gene therapy.

The research, published in Science Translational Medicine, found that gene therapy can elicit a regenerative response in pig hearts.
Shapiro and his research team first looked to small animals such as the zebrafish, which are able to regenerate heart tissue after a heart attack. This animal has a key protein at play, Cyclin A2 ( Ccna2 ).

After seeing the effects of CCna2 in small animals, researchers began looking at the effects of the gene in larger animals, such as pigs.
Investigators delivered Ccna2 directly into the heart and found that pigs not only had improved cardiac function, but also found evidence of cellular regeneration.

Ccna2 is a prenatal gene normally turned off in humans after birth. Shapiro believes using gene therapy as a tool for cardiac regeneration, optimized for humans, could lead to a viable treatment option for patients who suffer from myocardial infarction. ( Xagena )

Source: George Washington University, 2014

XagenaMedicine_2014



Indietro